Disease Model Development Services

As a leading research service provider, Protheragen has established itself as a trusted partner in the field of ophthalmic disease model development. With decades of expertise and a deep understanding of the complexity of eye-related pathologies, our team of experienced scientists is dedicated to providing specialized ophthalmic disease model development services to researchers and pharmaceutical companies for therapeutic development.

Disease Model Development in Ophthalmic Diseases

Ophthalmic disease model development encompasses the establishment of reliable and well-characterized in vitro, organoid, and in vivo systems that accurately recapitulate the key features and underlying mechanisms of various eye conditions. These models serve as invaluable platforms for advancing our understanding of disease pathogenesis, identifying novel therapeutic targets, and evaluating the efficacy and safety of potential therapeutics before clinical trials.

Fig.1 Schematic illustration of ocular structures and barriers. (Solanki A., et al., 2016)

The development of relevant and robust ophthalmic disease models is a critical step in bridging the gap between fundamental research and clinical application. By faithfully replicating the pathological hallmarks of human eye diseases, these models enable researchers to investigate disease mechanisms, screen drug candidates, and explore innovative therapeutic approaches with a high degree of translational relevance.

Ophthalmic Diseases Model Research

• The current status of ophthalmic diseases model research is marked by significant advancements in the field. Researchers have made progress in creating more accurate and physiologically relevant models that better mimic human disease conditions. This progress is evident in the development of gene-edited animal models, advanced organoid cultures, and sophisticated cell-based assays.
• These models are being used to study a variety of ophthalmic diseases, including retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, and corneal dystrophies. The integration of genomics, bioinformatics, and high-throughput screening technologies has further enhanced the predictive power and applicability of these models in drug discovery and development.

Our Services

Protheragen's ophthalmic disease model development services are designed to meet the complex needs of modern preclinical research. Our commitment to scientific excellence, customization, and ethical practice positions us as a leader in the field, supporting the advancement of ophthalmic disease research and the development of new therapeutics.

Cell-based Models Development Service

• Cell Line Development Service
• Primary Cell Development Service
• iPSC Development Service

Organoid Models Development Service

• Adult Stem Cell (ASC) Source
• Embryonic Stem Cell (ASC) Source
• Induced Pluripotent Stem Cell (iPSC) Source
• Patient-derived Organoid (POD)

Animal Models Development Services

• Surgical Models
• Genetically Engineered Models
• Humanized Animal Models
• Customized Animal Models

We offer customized model development services to meet the specific needs of each research project. Our team works closely with clients to understand their requirements and to design models that accurately replicate the disease of interest. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

Reference

• Solanki, Aum, et al. "Ocular drug delivery: impact of in vitro cell culture models." Nano-Biomaterials For Ophthalmic Drug Delivery (2016): 483-494.